Nattel S
Department of Medicine, Montreal Heart Institute, Quebec, Canada.
Cardiovasc Res. 1998 Mar;37(3):567-77. doi: 10.1016/s0008-6363(97)00293-9.
The major limitation to antiarrhythmic drug therapy is the risk of arrhythmia promotion, or 'proarrhythmia.' This complication may be lethal, and greatly restricts the value of antiarrhythmic agents, particularly for arrhythmias without an intrinsic mortality risk, such as atrial fibrillation. In order for improved antiarrhythmic drug therapy to be developed, it is essential to understand the fundamental mechanisms that cause proarrhythmic reactions to antiarrhythmic drugs. The present article reviews the experimental evidence that has been obtained regarding the mechanisms of proarrhythmia. The evidence available provides important insights, and points to potential strategies for developing newer and safer antiarrhythmic compounds.
抗心律失常药物治疗的主要局限性在于存在心律失常恶化或“促心律失常”的风险。这种并发症可能是致命的，极大地限制了抗心律失常药物的价值，尤其是对于那些本身没有死亡风险的心律失常，如心房颤动。为了开发出更好的抗心律失常药物治疗方法，了解导致对抗心律失常药物产生促心律失常反应的基本机制至关重要。本文综述了关于促心律失常机制的实验证据。现有证据提供了重要的见解，并指出了开发更新、更安全的抗心律失常化合物的潜在策略。
